Key Takeaways
- Pregabalin sale without prescription banned in Islamabad.
- Insulin shortage affects patients across Pakistan.
- Government warns of higher costs for alternative insulin brands.
The Health Department of Islamabad has announced a ban on the sale of pregabalin-containing medicines without a valid prescription, effective immediately. This directive, issued by the Pharmacy Services and Drug Control, aims to ensure the safe and regulated distribution of these medications.
According to the official announcement, pharmacies and pharmacists are required to strictly adhere to the new regulations. The ban is part of a broader effort to prevent misuse and ensure the availability of these drugs for legitimate medical purposes.
In related news, a shortage of a commonly used insulin product has been reported across Pakistan. The shortage is due to a year-long factory upgrade by the German manufacturer, which has significantly reduced the supply of rapid-acting insulin kits from 3,500 to just 1,000.
The health ministry has acknowledged the severity of the situation, warning that the disruption is not limited to Pakistan but is also affecting other regions, including Asia, Australia, and Europe. The government has assured the availability of alternative insulin products, but these are more expensive, with costs increasing by at least 20%.
Health experts caution that switching to alternative brands could have negative effects on patients, especially those with chronic conditions. The shortage has caused significant distress among patients who rely on this insulin for their daily lives.
The situation highlights the broader challenges faced by the pharmaceutical sector in Pakistan. Last year, the Pakistan Medical Association reported that at least 80 essential medicines, including those for cancer, diabetes, and cardiovascular disease, had become unavailable. The main factors cited include financial policy, supply disruptions, and domestic policy paralysis.
Additionally, the government has faced criticism for delaying the approval of retail prices for newly registered life-saving medicines, with around 40 such medicines remaining in regulatory limbo. Furthermore, 105 hardship-category medicines have had their price cases frozen for over two and a half years, leading to production halts by manufacturers.
The domestic pharmaceutical industry is also grappling with its own issues, as drug makers continue to push back on price controls. These challenges underscore the need for a comprehensive and coordinated approach to address the ongoing shortages and ensure the availability of essential medicines.
